2021 China New Design Hpma Cas No.27813-02-1 - FondaparinSodiuM;Fondaparinux SodiuM Identification;Fondaparinux sodium N-4; – JIN DUN

Short Description:

Product Detail

Product Tags

Feedback (2)

It is a great way to further improve our products and repair. Our mission is always to create innovative products to prospects with a superior expertise for Well Water Filter System, Paliperidone Palmitate, Sodium Carbonate Water Treatment, Competitive price with high quality and satisfying service make us earned more customers.we wish to work with you and seek common development.

2021 China New Design Hpma Cas No.27813-02-1 - FondaparinSodiuM;Fondaparinux SodiuM Identification;Fondaparinux sodium N-4; – JIN DUN Detail:

Fondaparinux Biological Activity

Describe	Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor。
Related Categories	signal path >> Metabolic enzymes/proteases >> Factor Xa Research areas >> Cardiovascular diseases
Target	Factor Xa[1]
In vitro studies	Fondaparinux sodium is the first new anticoagulant that selectively targets factor Xa. For Fondaparinux, the IC50 value (anti-Xa IU/ml) of activated monocytes (ac-M) is 0.59±0.05, and monocyte-derived particles (MMP) is 0.17±0.03 [2]。
In vivo research	Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium has 100% bioavailability, has a rapid onset of action, has a half-life of 14 to 16 hours, and can continue to resist thrombosis within 24 hours. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation [1]。
References	[1]. Bauer KA. et al. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S14-7.[2]. Ben-Hadj-Khalifa S, et al. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolysis. 2011 Jul;22(5):369-73.

Chemical and physical properties of Fondaparinux

Molecular formula	C31H53N3Na10O49S8
Molecular weight	1738.16
PSA	900.82000

Fondaparinux is a new type of antithrombotic drug that has been approved by the FDA after heparin and low molecular weight heparin for the treatment and prevention of a variety of arteriovenous thrombosis.

Indications: Fondaparinux is used for patients undergoing major orthopedic surgery of lower limbs, such as hip fracture, major knee surgery or hip replacement, to prevent venous thromboembolism. It is used for the treatment of patients with unstable angina or non-ST-segment elevation myocardial infarction who undergo urgent (<120 minutes) invasive treatment (PCI) without indication. It is used for the treatment of patients with ST-segment elevation myocardial infarction who use thrombolysis or initially do not receive other forms of reperfusion therapy.

1）Glaxo’s continuous market promotion will place it in the core drug position in the subsequent clinical path of the Ministry of Health, the price reform of the National Development and Reform Commission, and the medical insurance of the Ministry of People’s Insurance.

A、The product has not yet entered the national medical insurance. In 2010, the medical insurance adjustment has just entered the local medical insurance of 16 provinces. Sales are in the initial stage and will gradually replace the low-molecular-weight heparin market; medical insurance provinces: Shaanxi, Shanxi, Inner Mongolia, Liaoning, Tibet, Yunnan, Guangdong , Guangxi, Hainan, Jiangsu, Gansu, Fujian, Jiangxi, Henan, Hubei, Beijing.

B、The indications are still increasing. GSK currently has 3 indications in the clinic. For example, the indications for stents are exclusively approved. Other heparins are not available. The clinical application of stents increases by 30% every year. With the approval of new indications, sales will increase. In theory, all diseases treated by heparin series products can be treated by this product.

C、Price advantage, the minimum price of this product in the US market is 132 US dollars each, in China is 168 yuan, the domestic price will not drop. If you do export, the international market has broad space；

2) The technical threshold is high, the raw material is synthesized in 75 steps, and the patent has expired for 5 years (article in 2014). It has not been approved by other manufacturers. The synthesis is extremely difficult. It will not be done in less than 10 years. The cycle is long, difficult, and investment. high. There are few domestic competitors, and foreign competitors have high raw material costs. Our goal is to continuously reduce raw material costs and replace Glaxo in raw material production.
Hengrui Pharmaceuticals Fondaparinux was approved as the first imitation in China 2018.
Guangdong Runxing Biotechnology Co., Ltd. has an annual output of 210 kg of fondaparinux sodium advanced intermediate N3, which will be filed in 2018.

Fondaparinux was originally developed by MYLAN IRELAND. Currently, Hengrui Pharmaceuticals, Borui Pharmaceuticals, Haisco.

Product detail pictures:

Related Product Guide:

We have now probably the most innovative production equipment, experienced and qualified engineers and workers, regarded high quality control systems and also a friendly expert income team pre/after-sales support for 2021 China New Design Hpma Cas No.27813-02-1 - FondaparinSodiuM;Fondaparinux SodiuM Identification;Fondaparinux sodium N-4; – JIN DUN , The product will supply to all over the world, such as: belarus, Slovakia, Frankfurt, On today, we've got customers from all over the world, including USA, Russia, Spain, Italy, Singapore, Malaysia, Thailand, Poland, Iran and Iraq. The mission of our company is to deliver the highest quality products with best price. We've been looking forward to doing business with you!

Coagulant Flocculant